# Clear Labs

> Clear Labs is a San Carlos, California genomics company that builds Clear Dx, a fully automated next-generation sequencing platform. It turns whole genome sequencing - normally a slow, expert-heavy lab process - into a push-button diagnostic used by food manufacturers and public health labs to detect pathogens like Salmonella and Listeria, characterize SARS-CoV-2 and TB, and identify bacteria and fungi from clinical specimens, often with next-day results.

- **Founded:** 2014
- **Headquarters:** San Carlos, California, United States
- **Founders:** Sasan Amini (Co-Founder & CEO), Mahni Ghorashi (Co-Founder)
- **Team size:** ~86 employees
- **Products:** Clear Dx, Clear Safety, Clear Dx SARS-CoV-2 WGS, Clear Dx Microbial Surveillance WGS, Clear Dx Deeplex Myc-TB (with GenoScreen)
- **Notable:** Received FDA Emergency Use Authorization for its SARS-CoV-2 diagnostic (September 2020)., Deployed across more than 50% of US public health laboratories for SARS-CoV-2 whole genome sequencing (2021)., Earned AOAC International certification for its food safety platform (December 2019).

## Products & services

- **Clear Dx** — A fully automated, end-to-end next-generation sequencing (NGS) platform that combines robotics, sequencing, and bioinformatics so operators load samples and receive interpreted genomic results with minimal hands-on time.
- **Clear Safety** — Automated NGS program for routine food pathogen testing - detection and whole genome characterization of Salmonella and Listeria for food manufacturers; AOAC-certified and USDA NPIP-approved for Salmonella.
- **Clear Dx SARS-CoV-2 WGS** — Automated whole genome sequencing solution for SARS-CoV-2 detection and variant characterization, deployed across US public health laboratories during the COVID-19 pandemic.
- **Clear Dx Microbial Surveillance WGS** — Fully automated whole genome sequencing for bacterial and fungal isolates - up to 12 microbial isolates in about 27 hours with minutes of hands-on time.
- **Clear Dx Deeplex Myc-TB (with GenoScreen)** — Automated next-day solution for rapid tuberculosis and non-tuberculous mycobacteria identification with drug-resistance insights.
- **Clear Dx sterile-site clinical assay** — Automated NGS assay that identifies bacteria and fungi from sterile-site specimens with next-day results and minimal hands-on time.

## Achievements

- Received FDA Emergency Use Authorization for its SARS-CoV-2 diagnostic (September 2020).
- Deployed across more than 50% of US public health laboratories for SARS-CoV-2 whole genome sequencing (2021).
- Earned AOAC International certification for its food safety platform (December 2019).
- Approved under USDA's National Poultry Improvement Plan (NPIP) for Salmonella detection (October 2021).
- Raised roughly $171M in total across five funding rounds from top-tier investors.
- CEO Sasan Amini named one of the Top 50 Healthcare AI Entrepreneurs of 2025.

## Latest updates

- **2025-11** — Collaboration with Pillar Biosciences to extend Clear Labs automation into oncology NGS workflows, with early access beginning November 2025.
- **2025-08** — Launched Clear Dx Deeplex Myc-TB with GenoScreen - an automated next-day TB and NTM identification solution with drug-resistance insights.
- **2025-06** — Introduced an automated NGS assay identifying bacteria and fungi from sterile-site specimens with next-day results.
- **2025-01** — Closed a $30M Series D round led by a strategic investor with participation from existing backers.

## Links

- Website: https://clearlabs.com
- LinkedIn: http://www.linkedin.com/company/clear-labs
- Twitter/X: https://twitter.com/ClearLabsInc
- Facebook: https://facebook.com/ClearLabsInc/

---

Profile page: https://yespress.io/clear-labs
Published by YesPress — https://yespress.io
Last updated: 2026-07-13